Status:
COMPLETED
Efficacy And Safety Study Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Hypercholesterolemia
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the efficacy of Atorvastin vs Simvastatin in decreasing LDL-C in diabetic subjects with hypercholesterolemia at the end of the treatment phase.
Eligibility Criteria
Inclusion
- Diagnosis of type 2 diabetes mellitus
- LDL-C \> 130 mg/dL
Exclusion
- Insulin therapy
- Clinically relevant organ disease (creatininemia \>2mg/dL, CHF NYHA III and IV)
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
383 Patients enrolled
Trial Details
Trial ID
NCT00141141
Start Date
January 1 2004
End Date
April 1 2007
Last Update
February 18 2021
Active Locations (35)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
S. Benedetto DEL Tronto, Ascoli Piceno, Italy, 63039
2
Pfizer Investigational Site
S.Pietro Vernotico, Brindisi, Italy
3
Pfizer Investigational Site
Casarano, Lecce, Italy, 73043
4
Pfizer Investigational Site
Pavia, PV, Italy, 27100